Indications that the GLP-1 drug has greater benefits in the most frail patients should be viewed cautiously, one expert says.

Among the trends in the report are a growing proportion of younger adults with HF and worsening of racial disparities.

Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug Administration (FDA) provided market ...